Scholarlink

Objectives <p>Motility magnetic resonance imaging (mMRI) is a potential marker of disease activity of small bowel Crohn’s disease (SBCD), but there is limited data on its reproducibility. We assessed inter- and intra-observer agreement of small bowel motility as part of a prospective multicentre trial investigating whether mMRI can predict longer-term response to biologic therapy in active, non-stricturing SB-CD (MOTILITY Trial).</p> Methods <p>297 segmental small bowel motility scores from 104 SBCD patients (mean age 38.9 years, 43 female) recruited to the MOTILITY trial were measured independently by two radiologists experienced in mMRI, using GIQuant software. Twenty-six datasets were re-read by both radiologists to test intra-observer variability after a washout period of at least 6 weeks. Five gastrointestinal radiologists inexperienced in mMRI derived 66 segmental motility scores from the same 30 randomly selected patients. Agreement was quantified using the intra-class correlation coefficient (ICC).</p> Results <p>There was moderate agreement for mMRI-derived segmental small bowel motility measurements for both mMRI-experienced and inexperienced radiologists (ICC 0.59 (95% CI: 0.51, 0.66) and 0.70 (95% CI: 0.61, 0.78), respectively). Agreement remained moderate to good, combining the experienced trial MRI reader measurements with those of the five inexperienced radiologists (ICC 0.69 (95% CI: 0.61, 0.78). Intra-observer agreement for the two mMRI experienced radiologists was (0.71 (95% CI: 0.44, 0.86) and 0.70 (95% CI: 0.44, 0.86)).</p> Conclusions <p>There is moderate to good interobserver agreement for mMRI measurements of segmental small bowel motility for both experienced and inexperienced radiologists.</p> Critical relevance statement <p>Study findings support the continuing clinical translation of motility MRI as a reproducible biomarker of disease activity and treatment response in Crohn’s disease.</p> Key Points <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Motility MRI is a novel biomarker of small bowel Crohn’s disease activity.</p> </ItemContent> <ItemContent> <p>Currently, limited data on intra- and inter-observer variability exists.</p> </ItemContent> <ItemContent> <p>Motility MRI shows moderate to good inter- and intra-observer agreement.</p> </ItemContent> <ItemContent> <p>Intraclass correlation was 0.59–0.71 for experienced and inexperienced radiologists.</p> </ItemContent> <ItemContent> <p>Motility MRI is reproducible, supporting its utility as a biomarker of disease activity.</p> </ItemContent> </UnorderedList></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inter- and intra-observer variability of software quantified bowel motility measurements of small bowel Crohn’s disease: findings from the MOTILITY trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月27日

查看全文
  • Maira Hameed,
  • Andrew A. Plumb,
  • Kashfia Chowdhury,
  • Norin Ahmed,
  • Safi Rahman,
  • Gauraang Bhatnagar,
  • Elen Thomson,
  • Maryam Mohsin,
  • Jude Holmes,
  • Steve Halligan,
  • Stuart A. Taylor,
  • Tariq Ahmad,
  • Saiam Ahmed,
  • Fardowsa Ahmed-Timms,
  • Rachel Baldwin-Cleland,
  • Uday Bannur Chikkeragowda,
  • Nina Barratt,
  • Teresita Beeston,
  • Anisha Bhagwanani,
  • Stuart Bloom,
  • Darren Boone,
  • Biljana Brezina,
  • Amanda Cetroni,
  • Junaid Choudhury,
  • Bessie Cipriano,
  • Maria Dilawershah,
  • Heather Fitzke,
  • Tracy Foster,
  • James Franklin,
  • Anmol Gangi-Burton,
  • Nicola Gibbons,
  • Edmund Godfrey,
  • Arun Gupta,
  • Ailsa Hart,
  • Emma Helbren,
  • Anthony Higginson,
  • Judith Holmes,
  • Rachel Hyland,
  • Elizabeth Isaac,
  • Ilan Jacobs,
  • Roman Jastrub,
  • Mayamol Joseph,
  • Jaspreet Kaur,
  • Yakup Kilic,
  • Klaartje Bel Kok,
  • Felix Kpodo,
  • Shankar Kumar,
  • Hannah Lambie,
  • Sarah Langlands,
  • Eric Loveday,
  • Sara McCartney,
  • Alex Menys,
  • Peter Mooney,
  • Gordon Moran,
  • Felicia Onoviran,
  • Miles Parkes,
  • Anisha Patel,
  • Jaymin Patel,
  • Kamal Patel,
  • Kamini Patel,
  • Nishant Patodi,
  • Sue Philpott,
  • Richard Pollok,
  • Robert Przemiosolo,
  • Helen Rafferty,
  • Javen Ramsami,
  • Charlotte Robinson,
  • Suzanne Roffe,
  • Lindsay Rogers,
  • Konstantina Rosiou,
  • Naomi Sakai,
  • Abi Seward,
  • Harbir Sidhu,
  • Belinda Theis,
  • Nora Thoua,
  • Damian Tolan,
  • Simon Travis,
  • Anvi Wadke,
  • Lana Ward,
  • Annamaria Wilce,
  • Steven Williams

摘要

Objectives

Motility magnetic resonance imaging (mMRI) is a potential marker of disease activity of small bowel Crohn’s disease (SBCD), but there is limited data on its reproducibility. We assessed inter- and intra-observer agreement of small bowel motility as part of a prospective multicentre trial investigating whether mMRI can predict longer-term response to biologic therapy in active, non-stricturing SB-CD (MOTILITY Trial).

Methods

297 segmental small bowel motility scores from 104 SBCD patients (mean age 38.9 years, 43 female) recruited to the MOTILITY trial were measured independently by two radiologists experienced in mMRI, using GIQuant software. Twenty-six datasets were re-read by both radiologists to test intra-observer variability after a washout period of at least 6 weeks. Five gastrointestinal radiologists inexperienced in mMRI derived 66 segmental motility scores from the same 30 randomly selected patients. Agreement was quantified using the intra-class correlation coefficient (ICC).

Results

There was moderate agreement for mMRI-derived segmental small bowel motility measurements for both mMRI-experienced and inexperienced radiologists (ICC 0.59 (95% CI: 0.51, 0.66) and 0.70 (95% CI: 0.61, 0.78), respectively). Agreement remained moderate to good, combining the experienced trial MRI reader measurements with those of the five inexperienced radiologists (ICC 0.69 (95% CI: 0.61, 0.78). Intra-observer agreement for the two mMRI experienced radiologists was (0.71 (95% CI: 0.44, 0.86) and 0.70 (95% CI: 0.44, 0.86)).

Conclusions

There is moderate to good interobserver agreement for mMRI measurements of segmental small bowel motility for both experienced and inexperienced radiologists.

Critical relevance statement

Study findings support the continuing clinical translation of motility MRI as a reproducible biomarker of disease activity and treatment response in Crohn’s disease.

Key Points

Motility MRI is a novel biomarker of small bowel Crohn’s disease activity.

Currently, limited data on intra- and inter-observer variability exists.

Motility MRI shows moderate to good inter- and intra-observer agreement.

Intraclass correlation was 0.59–0.71 for experienced and inexperienced radiologists.

Motility MRI is reproducible, supporting its utility as a biomarker of disease activity.

Graphical Abstract